Rituximab

CAS 174722-31-7 3 FDA-DMF suppliersBiologic

Overview

Rituximab is a chimeric monoclonal antibody that targets the CD20 antigen on B lymphocytes, used primarily in the treatment of certain autoimmune diseases and types of cancer such as non-Hodgkin's lymphoma and chronic lymphocytic leukemia.

Therapeutic areas

OncologyImmunology

Related APIs

Lenalidomide
20 suppliers
Ibrutinib
16 suppliers
Thalidomide
11 suppliers
Nivolumab
2 suppliers
Paclitaxel
33 suppliers
Anastrozole
28 suppliers
Capecitabine
27 suppliers
Bicalutamide
26 suppliers

Ready to Accelerate Your
Discovery Workflow?

Find, vet, and source drug-manufacturing partners faster — with FDA compliance screening built in. Start free for 14 days.

Start free trialBook a demo